0UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT

     Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

       Date of Report (date of earliest event reported): January 13, 2016


                               CEL-SCI CORPORATION
                     --------------------------------------
             (Exact name of Registrant as specified in its charter)


        Colorado                       0-11503                   84-0916344
  --------------------            ------------------         -----------------
(State or other jurisdiction     (Commission File No.)      (IRS Employer
of incorporation)                                            Identification No.)


                         8229 Boone Boulevard, Suite 802
                             Vienna, Virginia 22182
                  --------------------------------------------
          (Address of principal executive offices, including Zip Code)


       Registrant's telephone number, including area code: (703) 506-9460


                                       N/A
                  --------------------------------------------
          (Former name or former address if changed since last report)


Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligations of the registrant under any of the
following provisions:

[ ]  Written  communications  pursuant  to Rule 425  under the  Securities  Act
     (17CFR 230.425)

[ ]  Soliciting  material  pursuant to Rule 14a-12  under the  Exchange Act (17
     CFR 240.14a-12)

[ ]  Pre-commencement  communications  pursuant  to  Rule  14d-2(b)  under  the
     Exchange Act (17 CFR 240.14d-2(b)

[ ]  Pre-commencement  communications  pursuant  to  Rule  13e-4(c)  under  the
     Exchange Act (17 CFR 240.13e-14c))

<PAGE>

Item 1.01   Entry Into a Material Definitive Agreement

     Item 1.01   Entry Into a Material Definitive Agreement

     On January 13, 2016 the Company sold  3,000,000  shares of its common stock
and 3,000,000 warrants to the de Clara Trust for $1,110,000.  The de Clara Trust
is controlled by Geert  Kersten,  the Company's  Chief  Executive  Officer and a
director.  Each  warrant  allows the de Clara Trust to purchase one share of the
Company's  common  stock at a price of $0.37  per share at any time on or before
January 13, 2021.

     On January 13, 2016 the  Company's  directors  also  approved the following
amendments to the Series N warrants held by the de Clara Trust.

     o    the exercise price of the warrants is $0.40 per share,

     o    the expiration date of the warrants is August 18, 2019,

     o    the warrants can be exercised on a cashless "basis",










                                       2
<PAGE>



                                   SIGNATURES

     Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.


Date:  January 13, 2016                CEL-SCI CORPORATION


                                       By: /s/ Patricia B. Prichep
                                           -------------------------------------
                                           Patricia B. Prichep,
                                           Senior Vice President of Operations
[{"type": "8-K", "sequence": "1", "filename": "form8kitem101declara1-16.txt", "description": "FORM 8-K ITEM 1.01", "secsgml_size_bytes": 3538}]
{"company-data": {"conformed-name": "CEL SCI CORP", "cik": "0000725363", "assigned-sic": "2836", "irs-number": "840916344", "state-of-incorporation": "CO", "fiscal-year-end": "0930"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "001-11889", "film-number": "161341634"}, "business-address": {"street1": "8229 BOONE BLVD .", "street2": "SUITE 802", "city": "VIENNA", "state": "VA", "zip": "22182", "phone": "7035069460"}, "mail-address": {"street1": "8229 BOONE BLVD.", "street2": "SUITE 802", "city": "VIENNA", "state": "VA", "zip": "22182"}, "former-company": {"former-conformed-name": "INTERLEUKIN 2 INC", "date-changed": "19880317"}}
0UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT

     Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

       Date of Report (date of earliest event reported): January 13, 2016

                               CEL-SCI CORPORATION
                     --------------------------------------
             (Exact name of Registrant as specified in its charter)

        Colorado                       0-11503                   84-0916344
  --------------------            ------------------         -----------------
(State or other jurisdiction     (Commission File No.)      (IRS Employer
of incorporation)                                            Identification No.)

                         8229 Boone Boulevard, Suite 802
                             Vienna, Virginia 22182
                  --------------------------------------------
          (Address of principal executive offices, including Zip Code)

       Registrant's telephone number, including area code: (703) 506-9460

                                       N/A
                  --------------------------------------------
          (Former name or former address if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligations of the registrant under any of the
following provisions:

[ ]  Written  communications  pursuant  to Rule 425  under the  Securities  Act
     (17CFR 230.425)

[ ]  Soliciting  material  pursuant to Rule 14a-12  under the  Exchange Act (17
     CFR 240.14a-12)

[ ]  Pre-commencement  communications  pursuant  to  Rule  14d-2(b)  under  the
     Exchange Act (17 CFR 240.14d-2(b)

[ ]  Pre-commencement  communications  pursuant  to  Rule  13e-4(c)  under  the
     Exchange Act (17 CFR 240.13e-14c))
Item 1.01   Entry Into a Material Definitive Agreement

     Item 1.01   Entry Into a Material Definitive Agreement

     On January 13, 2016 the Company sold  3,000,000  shares of its common stock
and 3,000,000 warrants to the de Clara Trust for $1,110,000.  The de Clara Trust
is controlled by Geert  Kersten,  the Company's  Chief  Executive  Officer and a
director.  Each  warrant  allows the de Clara Trust to purchase one share of the
Company's  common  stock at a price of $0.37  per share at any time on or before
January 13, 2021.

     On January 13, 2016 the  Company's  directors  also  approved the following
amendments to the Series N warrants held by the de Clara Trust.

     o    the exercise price of the warrants is $0.40 per share,

     o    the expiration date of the warrants is August 18, 2019,

     o    the warrants can be exercised on a cashless "basis",

                                       2
SIGNATURES

     Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.

Date:  January 13, 2016                CEL-SCI CORPORATION

                                       By: /s/ Patricia B. Prichep
                                           -------------------------------------
                                           Patricia B. Prichep,
                                           Senior Vice President of Operations